Luis Rigales Iii, MD
Family Medicine · Santa Fe, NMNPI 1033108972
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,000 of the $3,906 with a category attached, or 76.8%. AbbVie accounts for 79.7% of it on its own, with 8 other manufacturers making up the rest. 2022 is the largest year on record at $3,356, 6.3 times the $533 reported in 2019. Among family medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $144.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Boehringer Ingelheim$142
- Novo Nordisk$124
- GSK$118
- Lilly USA, LLC$115
- Pfizer$110
- plus $183 from 3 others
What the payments were for
- Speaking & faculty fees$3,00077%
- Food & beverage$89123%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $3,115 |
| Boehringer Ingelheim | 8 | $142 |
| Novo Nordisk | 1 | $124 |
| GSK | 1 | $118 |
| Lilly USA, LLC | 5 | $115 |
| Pfizer | 2 | $110 |
| BD | 1 | $100 |
| AstraZeneca | 4 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,906 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 56 | $73,062 |
| XareltoRivaroxaban | 39 | $53,922 |
| FarxigaDapagliflozin Propanediol | 22 | $32,989 |
| EliquisApixaban | 21 | $29,459 |
| JardianceEmpagliflozin | 16 | $27,804 |
| OzempicSemaglutide | 14 | $12,890 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $10,813 |
| Spiriva RespimatTiotropium Bromide | 17 | $10,564 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 13 | $7,762 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $6,764 |
| Atorvastatin Calcium | 507 | $6,003 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $5,562 |
| Tamsulosin Hcl | 214 | $3,725 |
| Rosuvastatin Calcium | 170 | $3,148 |
| Levothyroxine Sodium | 276 | $3,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $115 | $73,06256 claims |
| AstraZenecaFarxiga, Symbicort | $54 | $43,80265 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $142 | $38,36833 claims |
| PfizerEliquis | $110 | $29,45921 claims |
| Novo NordiskOzempic | $124 | $12,89014 claims |
| AbbVieSynthroid | $3,115 | $88325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Santa Fe
- Wendy JohnsonSanta Fe$37K
- Kurt KastendieckSanta Fe$7K
- Carl FriedrichsSanta Fe$7K
- Aryan CaireSanta Fe$3K
- Debra HigginbothamSanta Fe$3K
- Karla Moya-CritesSanta Fe$3K
- Gerzain ChavezSanta Fe$3K
- Harold McFarlingFarmington$160K
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.